{
    "2021-02-18": [
        [
            {
                "time": "",
                "orginal_text": "加速与互联网医疗、商业保险的融合，药企打着什么算盘？",
                "features": {
                    "keywords": [
                        "互联网医疗",
                        "商业保险",
                        "药企"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "医药行业2021年春季投资策略：供需皆强劲 业绩开门红",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "供需",
                        "业绩开门红"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药与健康护理行业周报：国内疫情向好 仍需紧密关注防控政策",
                "features": {
                    "keywords": [
                        "医药",
                        "健康护理",
                        "疫情向好",
                        "防控政策"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "健康护理"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "高瓴资本概念股多数调整，公牛集团、健帆生物、凯莱英、泰格医药、恩捷股份领跌",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "公牛集团",
                        "健帆生物",
                        "凯莱英",
                        "泰格医药",
                        "恩捷股份"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}